GLP-1 drugs in kidney disease
GLP-1 based medicines and kidney outcomes.
Key point
In CKD, GLP-1 receptor agonists were associated with fewer major adverse kidney events and lower albuminuria, primarily in type 2 diabetes, with gastrointestinal concerns.
From: Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis (Ren Fail, 2026 Dec) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 12, 9, 11, 16, 30.
New guidelines and consensus this year
- ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic SyndromeJ Am Soc Nephrol2026 Oct 1
- [SEMERGEN position paper on chronic kidney disease]Semergen2026 Apr
All papers from the last 12 months
371 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes with various ASCVD subtypes from a large tertiary referral centerAm J Prev Cardiol2026 DecPMID 42827863
- SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort studyJ Affect Disord2026 Dec 1PMID 42632571
- Anti-obesity medications in children and adolescents: blood pressure and chronic kidney disease implicationsPediatr Nephrol2026 DecPMID 42033464Review
- Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysisRen Fail2026 DecPMID 41644273Meta-analysisSystematic review
- Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implicationsCurr Opin Nephrol Hypertens2026 Nov 1PMID 42683763Review
- Association of GLP1-Receptor Agonists With Diabetic RetinopathyDiabetes Obes Metab2026 NovPMID 42660856
- Advances in Cardiovascular Pharmacotherapy. IX. Protection Against Major Adverse Cardiovascular Events by Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and ObesityJ Cardiothorac Vasc Anesth2026 NovPMID 42580924Review
- Pharmacological treatment of MASHDiabetologia2026 NovPMID 42467088Review
- Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysisAm J Surg2026 NovPMID 42173727
- Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trialLancet2026 Oct 17PMID 42815506RCT
More nephrology trends
All specialties →SGLT2 inhibitors in CKD
SGLT2 inhibitors to slow chronic kidney disease.
Key point: In non-diabetic CKD, renin-angiotensin system inhibitors and SGLT2 inhibitors would be indicated as the treatment of choice.
Acute kidney injury biomarkers
Biomarkers to detect and predict acute kidney injury.
IgA nephropathy
IgA nephropathy and the new targeted treatments being studied.
Lupus nephritis
Kidney involvement in lupus and its newer treatments.
Key point: Lupus nephritis management is increasingly individualized, with expanding treatment options, combination therapy, and a trend toward lower corticosteroid doses.
Complement inhibitors in kidney disease
Iptacopan, avacopan and other complement inhibitors in glomerular disease.
Key point: Complement inhibitors had no overall effectiveness or safety advantage over plasma therapy in atypical hemolytic uremic syndrome, except lower relapse rates.
APOL1 kidney disease
Kidney disease linked to APOL1 gene variants.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("GLP-1"[tiab] OR semaglutide[tiab] OR tirzepatide[tiab]) AND ("chronic kidney disease"[tiab] OR CKD[tiab] OR "kidney outcomes"[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.